Investors
We are committed to delivering our strategy and creating value for our shareholders.
Latest News
Latest Events
Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and nine months ended September 30, 2021 on
Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the
Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021
Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokinetics LONDON and RALEIGH, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,
Discover More
Verona Pharma
Investor Information
© Verona Pharma plc 2021. All rights reserved